NAS:GTHX (USA) Also Trade In: Germany
G1 Therapeutics Inc $ 20.85 0.175 (0.85%)
Warning! GuruFocus has detected 1 Severe warning sign with GTHX. Click here to check it out.
Avg Vol (1m):
Market Cap $:
Enterprise Value $:
Current and historical daily P/E ratio for G1 Therapeutics Inc () from 2017 to Jan 18 2021. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The P/E ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the P/E ratio is positive. Also for stocks with the same P/E ratio, the one with faster growth business is more attractive. G1 Therapeutics stock (GTHX) PE ratio as of Jan 18 2021 is 0. More Details
G1 Therapeutics PE Ratio (TTM) Historical Data
View and export this data going back to 2017. Start your Free Trial
G1 Therapeutics PE Ratio (TTM) Comparison
|Company||Market Cap(Mil)||PE Ratio (TTM)|
Compare NAS:KALA NAS:CDXS NAS:AVRO NAS:FIXX NAS:AKRO NYSE:KDMN NAS:ZIOP NAS:MTEM NAS:OYST NAS:ADAP OCSE:NOVO B ASX:CSL NAS:VRTX NAS:REGN XKRX:207940 NAS:SGEN NAS:MRNA NAS:ALXN XKRX:068270 NAS:INCY
Address 700 Park Offices Drive, Suite 200, Research Triangle Park, NC, USA, 27709
G1 Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel, small-molecule therapies to target unmet needs in the treatment of cancer. The firm is developing drugs that have the potential to treat most types of cancer such as cell lung cancer and breast cancer and designs them to combine - and enhance - the anti-tumor activity of current therapies.